Psychedelic medicines are expanding into the public consciousness

T HE COMING YEAR will see a number of milestones in the emerging era of psychedelic medicines. The recreational drug MDMA will complete a second phase-3 trial for the treatment of post-traumatic stress disorder ( PTSD). If this trial confirms the findings of the first, from 2021, then in 2023 MDMA will be considered by America’s Food and Drug Administration for approval.

Read More from the
Global Wellness News ™

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.